1. Academic Validation
  2. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control

  • Mediators Inflamm. 2016:2016:3094642. doi: 10.1155/2016/3094642.
Young-Sun Lee 1 Hee-Sook Jun 2
Affiliations

Affiliations

  • 1 Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea.
  • 2 Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea; College of Pharmacy and Gachon Institute of Pharmaceutical Science, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea; Gachon Medical Research Institute, Gil Hospital, Incheon 405-760, Republic of Korea.
Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating Insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 Receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating Enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.

Figures
Products